BIOABioAge Labs Inc.Healthcare · Biotechnologyas of 2026-09-25
Horizon

Issued 2026-09-25 at $7.05 · now $7.05 (2026-09-25, +0.0% since)

Based on its own history, a month from the 2026-09-25 close, BIOA has typically landed between $4.92 and $10.71 — a range of −30.3% to +51.9% from the issuance price $7.05.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

478 overlapping 1 month windows · 2024-09-26 – 2026-08-26 · basis climatology · forecast (batch). Base rate up 53.7% (90% CI 51.5–55.9%, ≈1,391 obs). Not a call on this stock — we have no evidence its odds differ.

The cone is anchored at the 2026-09-25 issuance close ($7.05) — the price the forecast resolves against on 2026-10-26, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where BIOA has typically landed a month from the 2026-09-25 close of $7.05 — the range is history, not a prediction.

$4.92worst · -30.3%$10.71best · +51.9%
  • now $7.05 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $7.19 (+2.0%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $6.18–$8.21
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $4.92–$10.71
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 478 windows spanning 2024-09-26 to 2026-09-25. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2024-11-11−79.8%−80.3%+0.0%
2024-11-13−79.5%−79.5%+0.0%
2024-11-14−79.0%−79.0%+3.0%
3 best
2025-12-12+78.0%−4.5%+78.0%
2025-12-17+73.3%+0.0%+86.3%
2025-12-15+72.6%−1.3%+83.9%

478 overlapping windows · 2024-09-26 – 2026-09-25 · not cherry-picked

Pending catalysts

  • 2026-11-30 — Trial primary completion: Phase 2 primary completion: A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors (source, as of 2026-08-14)

Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~2 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
50%
+11.4%
n=2
Feb
100%
+9.1%
n=2
Mar
0%
−20.1%
n=2
Apr
50%
+4.0%
n=2
May
50%
−1.6%
n=2
Jun
100%
+23.0%
n=2
Jul
100%
+4.0%
n=2
Aug
50%
−24.9%
n=2
Sep
50%
−3.3%
n=2
Oct
100%
+21.1%
n=2
Nov
50%
+2.5%
n=2
Dec
50%
−14.9%
n=2

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$25$52026-06-30: 1 insider sale, $509K — Barton Shane2026-06-29: 1 insider sale, $1.1M — Barton Shane2026-04-01: 1 insider sale, $157K — RUBIN PAUL D2026-03-02: 1 insider sale, $151K — RUBIN PAUL D2026-02-02: 1 insider sale, $139K — RUBIN PAUL D2026-01-13: 5 insider sales, $4.8M — Fortney Kristen, GOLDSTEIN DOV A MD …2026-01-02: 1 insider sale, $95K — RUBIN PAUL D2025-12-09: 1 insider sale, $216K — RUBIN PAUL D2025-12-04: 1 insider sale, $702K — RUBIN PAUL D2025-12: 2 open-market sales, $918K2026-01: 6 open-market sales, $4.9M2026-02: 1 open-market sale, $139K2026-03: 1 open-market sale, $151K2026-04: 1 open-market sale, $157K2026-06: 2 open-market sales, $1.6M↑ buys↓ salesofficer Barton Shane — Sale on 2026-06-30, filed 1 day after the tradeofficer Barton Shane — Sale on 2026-06-29, filed 2 days after the tradeofficer RUBIN PAUL D — Sale on 2026-04-01, filed 2 days after the tradeofficer RUBIN PAUL D — Sale on 2026-03-02, filed 1 day after the tradeofficer RUBIN PAUL D — Sale on 2026-02-02, filed 1 day after the tradedirector Fortney Kristen — Sale on 2026-01-13, filed 2 days after the tradedirector GOLDSTEIN DOV A MD — Sale on 2026-01-13, filed 2 days after the tradedirector GOLDSTEIN DOV A MD — Sale on 2026-01-13, filed 2 days after the tradedirector GOLDSTEIN DOV A MD — Sale on 2026-01-13, filed 2 days after the tradedirector GOLDSTEIN DOV A MD — Sale on 2026-01-13, filed 2 days after the tradeofficer RUBIN PAUL D — Sale on 2026-01-02, filed 4 days after the tradeofficer RUBIN PAUL D — Sale on 2025-12-09, filed 2 days after the tradeofficer RUBIN PAUL D — Sale on 2025-12-04, filed 1 day after the trade
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2026-06-30Barton ShaneofficerSale20,216 @ $25.19$509K−100.0% of holding+2.1%not yet — horizon still open0Form 4 · filed 1 day after the trade
2026-06-29Barton ShaneofficerSale42,350 @ $25.21$1.1M−100.0% of holding−9.5%not yet — horizon still open0Form 4 · filed 2 days after the trade
2026-04-01RUBIN PAUL DofficerSale8,820 @ $17.81$157K−100.0% of holding−15.3%not yet — horizon still open0Form 4 · filed 2 days after the trade
2026-03-02RUBIN PAUL DofficerSale7,433 @ $20.30$151K−100.0% of holding−14.4%−67.7%0Form 4 · filed 1 day after the trade
2026-02-02RUBIN PAUL DofficerSale7,433 @ $18.75$139K−100.0% of holding+6.3%−56.7%0Form 4 · filed 1 day after the trade
2026-01-13Fortney KristendirectorSale233,107 @ $18.12$4.2M−19.3% of holding−1.8%−1.7%976,949Form 4 · filed 2 days after the trade
2026-01-13GOLDSTEIN DOV A MDdirectorSale11,663 @ $20.54$240K−32.4% of holding−1.8%−1.7%24,331Form 4 · filed 2 days after the trade
2026-01-13GOLDSTEIN DOV A MDdirectorSale8,974 @ $18.43$165K−18.2% of holding−1.8%−1.7%40,434Form 4 · filed 2 days after the trade
2026-01-13GOLDSTEIN DOV A MDdirectorSale4,440 @ $19.45$86K−11.0% of holding−1.8%−1.7%35,994Form 4 · filed 2 days after the trade
2026-01-13GOLDSTEIN DOV A MDdirectorSale1,923 @ $21.08$41K−7.9% of holding−1.8%−1.7%22,408Form 4 · filed 2 days after the trade
2026-01-02RUBIN PAUL DofficerSale7,433 @ $12.85$95K−100.0% of holding+54.3%+80.2%0Form 4 · filed 4 days after the trade
2025-12-09RUBIN PAUL DofficerSale18,000 @ $12.00$216K−100.0% of holding+14.4%+27.8%0Form 4 · filed 2 days after the trade
2025-12-04RUBIN PAUL DofficerSale68,897 @ $10.19$702K−100.0% of holding+45.4%+39.1%0Form 4 · filed 1 day after the trade
2024-10-03Pande Vijay SatyananddirectorPurchase25,306 @ $19.90$504K+2.3% of holding+4.5%−73.4%1,119,195Form 4 · filed same day
2024-10-02Pande Vijay SatyananddirectorPurchase67,096 @ $19.73$1.3M+6.5% of holding+19.7%−72.9%1,093,889Form 4 · filed 1 day after the trade
2024-10-01Pande Vijay SatyananddirectorPurchase126,793 @ $19.73$2.5M+14.1% of holding+19.7%−73.2%1,026,793Form 4 · filed 2 days after the trade
2024-09-27Pande Vijay SatyananddirectorPurchase900,000 @ $18.00$16.2Mownership Δ n/a+13.4%−82.8%900,000Form 4 · filed same day
2024-09-27HEALY JAMESdirectorPurchase588,888 @ $18.00$10.6M+35.9% of holding+13.4%−82.8%2,227,124Form 4 · filed same day
2024-09-27Cormorant Asset Management, LPotherPurchase450,000 @ $18.00$8.1M+38.2% of holding+13.4%−82.8%1,629,529Form 4 · filed 4 days after the trade
2024-09-27ENRIGHT PATRICK GdirectorPurchase400,000 @ $18.00$7.2M+30.5% of holding+13.4%−82.8%1,710,589Form 4 · filed same day
2024-09-27HEALY JAMESdirectorPurchase26,497 @ $18.00$477Kownership Δ n/a+13.4%−82.8%26,497Form 4 · filed same day
2024-09-27HEALY JAMESdirectorPurchase21,814 @ $18.00$393Kownership Δ n/a+13.4%−82.8%21,814Form 4 · filed same day
2024-09-27HEALY JAMESdirectorPurchase18,353 @ $18.00$330Kownership Δ n/a+13.4%−82.8%18,353Form 4 · filed same day
2024-09-27HEALY JAMESdirectorPurchase11,113 @ $18.00$200Kownership Δ n/a+13.4%−82.8%11,113Form 4 · filed same day
2024-09-27Barton ShaneofficerPurchase2,632 @ $18.00$47Kownership Δ n/a+13.4%−82.8%2,632Form 4 · filed 164 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

115 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-06-30Barton ShaneofficerOption exercise4,2904,290Form 4
2026-06-30Barton ShaneofficerOption exercise7,86120,216Form 4
2026-06-30Barton ShaneofficerOption exercise4,0008,290Form 4
2026-06-30Barton ShaneofficerOption exercise4,06512,355Form 4
2026-06-30Barton ShaneofficerOption exercise7,86167,941Form 4
2026-06-30Barton ShaneofficerOption exercise4,00017,016Form 4
2026-06-30Barton ShaneofficerOption exercise4,29013,299Form 4
2026-06-30Barton ShaneofficerOption exercise4,06526,977Form 4
2026-06-29Barton ShaneofficerOption exercise9,30111,933Form 4
2026-06-29Barton ShaneofficerOption exercise14,19842,350Form 4
2026-06-29Barton ShaneofficerOption exercise7,26119,194Form 4
2026-06-29Barton ShaneofficerOption exercise8,95828,152Form 4
2026-06-29Barton ShaneofficerOption exercise8,95831,042Form 4
2026-06-29Barton ShaneofficerOption exercise7,26121,016Form 4
2026-06-29Barton ShaneofficerOption exercise14,19875,802Form 4
2026-06-29Barton ShaneofficerOption exercise9,30117,589Form 4
2026-06-10Davidson Michael H.directorAward / grant22,00022,000Form 4
2026-06-10GARNIER JEAN PIERREdirectorAward / grant22,00022,000Form 4
2026-06-10HEALY JAMESdirectorAward / grant22,00022,000Form 4
2026-06-10ENRIGHT PATRICK GdirectorAward / grant22,00022,000Form 4
2026-06-10Hemrajani RekhadirectorAward / grant22,00022,000Form 4
2026-06-10Pande Vijay SatyananddirectorAward / grant22,00022,000Form 4
2026-04-23GOLDSTEIN DOV A MDdirectorOption exercise3,54236,575Form 4
2026-04-23GOLDSTEIN DOV A MDdirectorOption exercise3,542155,833Form 4
2026-04-01RUBIN PAUL DofficerOption exercise5,4375,437Form 4
2026-04-01RUBIN PAUL DofficerOption exercise3,3838,820Form 4
2026-04-01RUBIN PAUL DofficerOption exercise5,4370Form 4
2026-04-01RUBIN PAUL DofficerOption exercise3,3830Form 4
2026-03-02RUBIN PAUL DofficerOption exercise5,4335,433Form 4
2026-03-02RUBIN PAUL DofficerOption exercise2,0007,433Form 4
2026-03-02RUBIN PAUL DofficerOption exercise2,0003,383Form 4
2026-03-02RUBIN PAUL DofficerOption exercise5,4335,437Form 4
2026-03-01GOLDSTEIN DOV A MDdirectorOption exercise3,54233,033Form 4
2026-03-01GOLDSTEIN DOV A MDdirectorOption exercise3,542159,375Form 4
2026-02-17RUBIN PAUL DofficerAward / grant110,000110,000Form 4
2026-02-17Morgen EricdirectorAward / grant110,000110,000Form 4
2026-02-17Fortney KristendirectorAward / grant330,000330,000Form 4
2026-02-17Morgen EricdirectorAward / grant12,50012,500Form 4
2026-02-17GOLDSTEIN DOV A MDdirectorAward / grant110,000110,000Form 4
2026-02-17Barton ShaneofficerAward / grant45,00045,000Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.